The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASDNew features and the ‘Ten Commandments’ of the 2019 Guidelines are discussed by Professor Peter J. Grant and Professor Francesco Cosentino, the Task Force chairmen

The most clinically relevant new aspects of the 2019 version of the ESC Guidelines compared with the previous version published in 2013 relate to:Reclassification of cardiovascular (CV) risk.Individualized blood pressure (BP) targets.New lipid targets relating to severity of CV risk.Recommendations for the use of PCSK9 inhibitors in lipid management.New recommendations regarding the role of aspirin and the novel oral anticoagulants (NOACs) in diabetes.New recommendations for the duration of dual antiplatelet therapy post-ACS in diabetes mellitus (DM).The interpretation of the CV outcome trials in diabetes therapies and the new recommendations for their place in the management and prevention of CV disease in Type 2 diabetes.New recommendations regarding the use of SGLT2i and GLP-1 agonists in slowing the decline in renal function in Type 2 diabetes with chronic kidney disease (CKD).The repositioning of metformin in the management of Type 2 diabetes.Choice of revascularization techniques in CAD which depends on the complexity of the underlying disease.
Source: European Heart Journal - Category: Cardiology Source Type: research